BioInvent to present promising clinical data at ASCO and EHA
In the coming weeks, BioInvent is set to present three significant data sets at the American Society for Clinical Oncology’s (ASCO) annual congress and the European Hematology Association’s (EHA) annual meeting. At ASCO, BioInvent will showcase advancements with BI-1808 monotherapy and BI-1206 in combination with Keytruda. At EHA, promising data on BI-1206 will be presented to the expert community.
On May 14, 2024, BioInvent announced that promising clinical data for BI-1206 in relapsed/refractory non-Hodgkin lymphoma (NHL), dosed in combination with rituximab, will be presented in a poster at the European Hematology Association congress held in Madrid, Spain from June 13-16, 2024. Read more here.
Promising clinical data for BI-1808 – a potential new class of immunomodulatory agent
The company has made notable advances with the company’s anti-TNFR2 antibody BI-1808. The new findings to be presented at ASCO indicate promising early signs of single agent efficacy and a robust safety profile for this anti-TNFR2 program.
Initial efficacy and safety data from the ongoing phase I/IIa study show one complete response, one partial response that is still improving, and nine patients with stable disease in the single agent arm of BI-1808.
BioInvent is also strengthened with promising signals of efficacy and a favourable safety profile in the phase I dose escalation part studying BI-1808 in combination with Keytruda.
BioInvent’s CEO Martin Welschof commented on the progress:
“These data evaluating BI-1808 as single agent and in combination with pembrolizumab in patients with solid tumors support our belief that BI 1808 could represent a new class of immunomodulatory agent with the potential to improve the efficacy of cancer therapy. These strong signals of antitumoral activity, especially in these heavily pre-treated patients, are very encouraging and we look forward to presenting these data at the prestigious ASCO conference.”
More positive data for BI-1206 in solid tumours
The data package supporting BioInvent’s other lead product, BI-1206 continues to grow, and the company reported new clinical results in late May showing promising and durable responses in patients who previously failed on anti-PD-1/L1 therapy. This data lends support to BioInvent’s belief that BI-1206 could enhance the effect of anti-PD-1/L1 therapies, as a major challenge for treating physicians today is that patients either do not respond or stop responding to current standard of care checkpoint inhibitor treatments. Importantly, the data also showed the combination was well-tolerated in this heavily pre-treated population of patients.
The data shows a complete response; a partial response, and seven patients with stable disease, including one long-lasting out of 24 evaluable patients. In addition, it has now also been noted that the subcutaneous administration of BI-1206, which develops in parallel with intravenous administration, is well tolerated without any notable injection reactions.
The company’s Chief Medical Officer Andres McAllister comments on the progress in a press release:
“The ability to induce responses in heavily pre-treated patients, including two durable responses and a stable disease lasting for more than 24 months, is encouraging and supports the importance of blocking FcyRIIB to enhance the activity of immune checkpoint inhibitors.”
New findings BI-1206 in NHL to be presented at EHA
First data for the SC arm of BI-1206 in NHL show 1 complete response (CR), 2 partial response (PR), 1 stable disease (SD) out of 4 evaluable patients. In the IV arm; a fifth CR has been observed, adding to a total of 5 CR, 1 PR and 6 SD out of 17 evaluable patients. Based on these encouraging results, BioInvent plans to initiate a phase IIa study arm where the BTK inhibitor, acalabrutinib (Calquence), will be added to the rituximab and BI-1206 combination, which is expected to further increase response rates.
Martin Welschof commented:
“There is a high unmet need to develop treatments that can overcome resistance and improve the durability of responses to rituximab, an essential part of NHL treatment. We believe BI-1206 has the potential to meet this need. To identify the best options and meet the needs of clinicians and patients, we are evaluating BI-1206 administration as both IV and SC. IV dosing so far has produced response rates of a 35% ORR (overall response rate), 29% CRR (cumulative response rate) and 71% DCR (disease control rate), and we see promising early efficacy data from the subcutaneous dosing. In addition, we report an ORR of 56% in the subset of patients with follicular lymphoma (FL).”
Progress reflected in rising stock price
BioInvent’s progress over the past year and particularly in recent months, has caught the attention of market participants. The company’s stock has surged nearly one hundred percent in three months, positioning BioInvent as one of this year’s most successful investments on the Scandinavian stock market.
BioInvent appears committed to maintaining this current trajectory and positive momentum: In addition to presenting its promising new data to the global expert community at ASCO and EHA, BioInvent will soon turn its attention to Key Opinion Leaders to promote its drug candidates.
The company will host a virtual KOL event on Tuesday, June 18, 2024, to discuss the recently presented clinical efficacy and safety data from BI-1808 and BI-1206, as well as TNFR2 and FcyRIIB as promising targets in immuno-oncology. Read more here.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
